Fennec Pharmaceuticals Reports Q3 Earnings Beat with $19.4 Million Revenue
Fennec Pharmaceuticals (NASDAQ: FENC) reported third-quarter financial results that exceeded analyst expectations for both earnings and revenue. The company posted a GAAP EPS of $0.12, surpassing estimates by $0.02, while total revenue reached $19.4 million, representing a 55.2% increase year-over-year. The company demonstrated significant profitability improvements, reporting a net income of $4.6 million compared to a net loss of $638,000 in the same period last year. Additionally, non-GAAP adjusted EBITDA rose sharply to $5.8 million from $2 million in the prior year's third quarter.
Tickers: $FENC